Figure 7: Receiver-operator characteristic (ROC) curve of CD4CD69 positivity. Predictive potential of the percentage of CD4CD69-positive cells at baseline (start of anti-TNF) to long-term response to therapy. CD4+CD69+ T-cell percentage < 2.43 has the highest likelihood ratio (4.29 (CI: 0.58–1.06) to discriminate between future anti-TNF responders and nonresponders (sensitivity: 71.4%, specificity: 83.3%, ).